Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for pharmaceutical industry professionals · Tuesday, October 15, 2019 · 499,251,833 Articles · 3+ Million Readers

Global Epilepsy Market 2018-2035: Forecast, Treatment, Epidemiology, Marketed Drugs, Pipeline

/EIN News/ -- Dublin, June 24, 2019 (GLOBE NEWSWIRE) -- The "Epilepsy Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Market Snapshot

  • Label expansions will drive uptake of newer brands, sustaining the epilepsy market by countering widespread genericization.
  • Levetiracetam, valproate formulations, lamotrigine, and carbamazepine constitute the mainstay of epilepsy treatment.
  • Although approximately 70% of epilepsy patients respond to treatment, the number of prevalent cases of active epilepsy remains high.
  • UCB will continue to dominate the epilepsy market with key drugs Keppra and Vimpat.
  • With positive Phase III data in LGS, Epidiolex is proving to be the therapy of choice for refractory childhood epilepsy.

Key Topics Covered

FORECAST: EPILEPSY
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Aptiom/Zebinix (Eslicarbazepine)
Banzel/Inovelon (Rufinamide)
Briviact (Brivaracetam)
Epidiolex (Cannabidiol)
Fycompa (Perampanel)
Keppra/Keppra Xr (Levetiracetam)
Lamictal/Lamictal Xr (Lamotrigine)
Lyrica (Pregabalin)
Onfi (Clobazam)
Vimpat (Lacosamide)
Primary Research Methodology

TREATMENT: EPILEPSY
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Treatment Dynamics
Unmet Needs In Epilepsy

EPIDEMIOLOGY: EPILEPSY
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: EPILEPSY
Overview
Executive Summary
Product Overview
Product Profile: Aptiom
Product Profile: Banzel
Product Profile: Briviact
Product Profile: Fycompa
Product Profile: Keppra And Keppra Xr
Product Profile: Lamictal And Lamictal Xr
Product Profile: Lyrica
Product Profile: Onfi
Product Profile: Vimpat

PIPELINE: EPILEPSY
Overview
Executive Summary
Clinical Pipeline Overview
Latest Analyst Opinion
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Epidiolex
Product Profile (Late Stage): Ganaxolone

For more information about this report visit https://www.researchandmarkets.com/r/2du8us

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Central Nervous System Drugs 
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release